Please login to the form below

Not currently logged in
Email:
Password:

Roche signs exclusive distribution deal

Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment
Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment.

The K-RAS test will aid in the selection of suitable colorectal cancer patients for treatment, whereas the EGFR 29 test will aid doctors in selecting lung cancer patients suitable for treatment with some inhibitor therapies.

The European Commission recently granted a conditional marketing authorisation for a potential treatment for patients with non-mutated K-RAS genes who do not respond to standard chemotherapy regimens.

Daniel O'Day, president and CEO of Roche Molecular Diagnostics said: "There is a growing demand for tests to indicate disease prognosis and identify patient groups more likely to benefit from a particular drug."

Roche has been granted exclusive worldwide distribution rights for the K-RAS test, and exclusive distribution rights inall global markets except the US, Canada, Mexico and Hong Kong for the EGFR 29 test. Both tests have CE Mark certification in Europe.

"Not only does it [the distribution agreement] enable us to meet the growing demand for these tests, but it also gives doctors and patients access to standardised test results that provide further information to enhance treatment decisions," said Dr Stephen Little, CEO of DxS.

2nd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics